Topic experts discuss the risk of DILI and phenotypes of presentation from children to the elderly. Presenters review emerging and novel therapies associated with DILI, provide an update on blood-based biomarkers of DILI, and highlight research priorities to address knowledge gaps in this constantly evolving space.

Join in the fun with the 3rd iteration of the popular (standing room only in 2024) and only (thank goodness) hepatotoxicity-themed game show at The Liver Meeting. The style and format of this workshop is loosely based on the NPR game show, &quot;Wait wait...Don&#39;t Tell Me!&quot;. The Hepatotoxicity Special Interest Group has assembled a panel of experts to address cutting-edge topics in DILI and mechanisms of hepatotoxicity. Speakers present in a &quot;speed data&quot; format, with the majority of time left for discussion and engagement with panelists and the audience. Speakers are introduced by ridiculous limericks anchored in the topic of the presentation rather than extensive CVs. The session features audience participation in a competition to win a unique AASLD Wait Wait...Don&#39;t DILI! mug.&nbsp;<br />
<br />
<strong>Slido:&nbsp;<a href="https://app.sli.do/event/wEwW966F9oGMuNmEr35rwh">https://app.sli.do/eve…;

Acute-on-chronic liver failure (ACLF) is the focus of this joint symposium from AASLD and the Asian Pacific Association for the Study of the Liver (APASL). ACLF is a complex syndrome characterized by acute hepatic decompensation in the setting of chronic liver disease leading to multiorgan failure and high short-term mortality. However, the definition, classification, and management strategies for ACLF vary significantly between APASL and AASLD guidelines. The program begins with an in-depth exploration of ACLF definitions as per APASL and AASLD, highlighting key clinical differences via case-based presentations. Expert discussions follow focusing on management strategies from both AASLD and APASL perspectives. While AASLD emphasizes early liver transplantation and intensive care, APASL advocates for aggressive medical management, including liver regeneration therapies. Understanding these distinct approaches is crucial for optimizing patient care, particularly in resource-limited settings.

Join this interactive session that focuses on the diagnosis and management of sinusoidal obstruction syndrome and veno-occlusive disease. Topics include current diagnostic approaches for sinusoidal obstruction syndrome/veno-occlusive disease, available therapies, natural history of the condition, and patient prognosis.

Welcome to your first experience of The Liver Meeting! Join us at the First Timer Meet-Up, a special event designed to welcome new attendees and help you make the most of your experience. This casual, friendly gathering is the perfect opportunity to:
<ul>
<li>Meet fellow first-time attendees from around the world.</li>
<li>Connect with esteemed AASLD members.&nbsp;</li>
<li>Learn how to navigate the meeting and optimize your time.</li>
<li>Ask questions and get insider tips.</li>
<li>Begin building your professional network in hepatology.</li>
</ul>
Whether you&#39;re a trainee, early-career professional, or new to the field, this event will help you feel at home and ready to dive into everything The Liver Meeting&reg; has to offer.

Prepared by the Practice Guidelines Committee, this session highlights newly published AASLD guidelines addressing critical issues regarding treatment of viral hepatitis B. Speakers also present an extensive list of topics pertaining to liver transplantation in adults ranging from pretransplant evaluation to management of various graft-related and nongraft-related postoperative complications.

Delve into the complexities of liver transplantation among patients with alcohol-associated liver disease (ALD). Topics include the clinical and logistical resources required, ethical considerations—especially in living donor contexts—and the critical role of relapse prevention and psychosocial support in long-term outcomes.

Speakers provide updates on novel herbal and dietary supplements that may potentially cause liver injury, including but are not limited to green tea extracts, curcumin/turmeric, ashwagandha, kratom, black cohosh, garcinia cambogia, and red yeast extract. Topics include specific signatures and patterns of liver enzymes associated with liver injury due to ingestion of selected herbal compounds and over-the-counter medications, and compounds that are considered to present minimal risk for DILI.

Experts explore the complex interplay between cardiovascular and liver health, focusing on the challenges and opportunities in managing patients with cardiac-associated liver disease. Through a multidisciplinary lens, the session focuses on the impact of cardiovascular disease on end-stage liver disease; strategies for cardiovascular assessment in patients with advanced liver disease; and evidence-based approaches to optimize outcomes in this unique patient population. Speakers share insights to foster a collaborative framework for comprehensive patient care.

Presenters review recent advances in our understanding of sexual dimorphism in the liver and its contribution to liver growth, metabolism, and disease. The concepts covered by the thought leaders and content experts include the effect of sex hormones on hepatocyte proliferation and sex-specific differences in metabolic demands. They also cover concepts of sexually dimorphic responses in specific chronic pathologies including MASLD and HCC. Sex as a biological variable is often overlooked, which can result in delayed or inappropriate treatment. However, because the liver responds differently in males and females, this important variable needs to be considered both in experimental design and interpretation.